ReviewFrontiers in immunology2020
Airway Natural Killer Cells and Bacteria in Health and Disease.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Trial
- Mucosal immunity: mechanism and application in cancer immunotherapy.Journal of hematology & oncology · 2026Review
- In Vitro Effects of the Three Actives IL-12 (5 CH), IFN-γ (6 CH), and TNF-α (5 CH) from the Micro-Immunotherapy Medicine 2LEID-NCurrent issues in molecular biology · 2026Article
- Immune evasion of multidrug-resistant bacteria: insights from lung innate immune cells and targeted therapies.Frontiers in cellular and infection microbiology · 2026Review
- Adrenergic receptors: a key determinant of outcomes in bacterial pneumonia and bacterial sepsis-associated acute lung injury/acute respiratory distress syndrome through participation in pulmonary innate immune response.Frontiers in immunology · 2026Review
- Genetically defined causal effects of natural killer cells related traits in risk of infection: a Mendelian randomization study.BMC infectious diseases · 2024Article
- Effect of Granzyme K, FasL and Interferon-γ Expression in Placentas with Preeclampsia.Biomedicines · 2024Article
- Natural Killer Cells as a Further Insight into the Course of Chronic Obstructive Pulmonary Disease.Biomedicines · 2024Article
- Clinical value of CD3American journal of translational research · 2024Article
- Dynamic immune signatures of patients with advanced non-small-cell lung cancer for infection prediction after immunotherapy.Frontiers in immunology · 2024Article
- Natural killer cells in the lung: potential role in asthma and virus-induced exacerbation?European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Associations of Smoking, Cytomegalovirus Serostatus, and Natural Killer Cell Phenotypes in Smokers With and At Risk for COPD.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2023Article
- Streptococcus pneumoniae drives specific and lasting Natural Killer cell memory.PLoS pathogens · 2023Article
- Host Immune Regulation in Implant-Associated Infection (IAI): What Does the Current Evidence Provide Us to Prevent or Treat IAI?Bioengineering (Basel, Switzerland) · 2023Review
- Immunometabolic Signature during Respiratory Viral Infection: A Potential Target for Host-Directed Therapies.Viruses · 2023Review
- Early innate cell interactions withFrontiers in immunology · 2023Review
- Sex difference in innate inflammatory response and macrophage polarization in Streptococcus agalactiae-induced pneumonia and potential role of microRNA-223-3p.Scientific reports · 2022Article
- Characterization of Immune Cells From the Lungs of Patients With Chronic Non-Tuberculous Mycobacteria orImmune network · 2022Article
- Mucosa-Associated Invariant T Cell Hypersensitivity toJournal of immunology (Baltimore, Md. : 1950) · 2022Article
- Staphylococcal trafficking and infection-from 'nose to gut' and back.FEMS microbiology reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells are innate lymphoid cells at the interface between innate and adaptive immunity and mostly studied for their important roles in viral infections and malignant tumors. They can kill diseased cells and produce cytokines and chemokines, thereby shaping the adaptive immune response. Nowadays, NK cells are considered as a strong weapon for cancer immunotherapy and can for example be transduced to express tumor-specific chimeric antigen receptors or harnessed with therapeutic antibodies such as the so-called NK engagers. Whereas a large body of literature exists about the antiviral and antitumoral properties of NK cells, their potential role in bacterial infections is not that well delineated. Furthermore, NK cells are much more heterogeneous than previously thought and have tissue-characteristic features and phenotypes. This review gives an overview of airway NK cells and their position within the immunological army dressed against bacterial infections in the upper and predominantly the lower respiratory tracts. Whereas it appears that in several infections, NK cells play a non-redundant and protective role, they can likewise act as rather detrimental. The use of mouse models and the difficulty of access to human airway tissues for ethical reasons might partly explain the divergent results. However, new methods are appearing that are likely to reduce the heterogeneity between studies and to give a more coherent picture in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.